Skip to main content
Premium Trial:

Request an Annual Quote

10x Genomics Sues Parse Bio for Patent Infringement, Seeks Injunction

NEW YORK – 10x Genomics has sued Parse Biosciences, a competitor in the single-cell transcriptomics market, alleging patent infringement.

In a complaint filed Thursday in the US District Court for the District of Delaware, 10x alleged that Parse's Evercode Whole-Transcriptome assay and other planned products infringe six patents owned by or exclusively licensed to 10x.

Specifically, 10x said that Parse's Evercode WT product infringes US Patent Nos. 10,155,981; 10,697,013; and 10,240,197, all titled "Methods for analyzing nucleic acids from single cells."

Parse's planned single-cell ATAC-seq (assay for transposase-accessible chromatin by sequencing) will infringe US Patent Nos. 10,150,995; 10,619,207; and 10,738,357, all titled "Transposition of native chromatin for personal epigenomics," according to the complaint.

The company asked the court for a declaratory judgement that Parse infringes its patents and an injunction against the alleged infringement, as well as a trial by jury. 10x also seeks damages and royalties.

"Parse is a single-cell genomics company that has made clear that it intends nothing less than to copy 10x's complete lineup of single-cell products wholesale," 10x alleged, referencing an April GenomeWeb story that revealed Parse's plans for early-access programs for targeted single-cell RNA sequencing and a single-cell CRISPR assay, as well development of a single-cell ATAC-seq assay.

"10x has invested more than $1 billion in R&D to invent and bring to market breakthrough technologies that have catalyzed a revolution in genomics," a 10x spokesperson said in an email. "We will protect our investments and vigorously defend our products and broad intellectual property portfolio against infringement." 

"Through Evercode, Parse offers a fundamentally differentiated solution that makes single-cell sequencing more scalable without the need for expensive microfluidic instruments," Parse CEO and Cofounder Alex Rosenberg said in a statement. "This lawsuit is without merit, and we will defend ourselves vigorously. We will not let competition prevent us from making single-cell genomics more accessible to the broader community."

Pleasanton, California-based 10x offers the popular Chromium platform for droplet-based single-cell transcriptomics and multimodal analysis and has been one of the first companies to develop spatial transcriptomics technology.

Parse, a University of Washington spinout, offers plate-based single-cell assays. It announced $7 million in Series A funding in January 2021.

The lawsuit makes Parse the latest of 10x's competitors to be hit with a patent lawsuit. In 2020, 10x won a declaration making it the exclusive licensee for a key patent that had also been licensed to single-cell firm 1Cellbio. And last year, 10x settled a tangle of lawsuits over single-cell IP involving Bio-Rad Laboratories and single-cell instrument maker Celsee, resulting in a global cross-licensing and royalty deal.

In the last year, 10x has launched a new wave of lawsuits over spatial genomics technology, alleging patent infringement by NanoString Technologies and Vizgen.

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.